相关临床试验
1254
159 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
终止
72
5.7%
招募中
161
12.8%
暂停
5
0.4%
撤回
70
5.6%
进行中（未招募）
93
7.4%
Unknown
73
5.8%
已完成
714
56.9%
Enrolling By Invitation
10
0.8%
尚未招募
56
4.5%
- A modeling study in The Lancet estimates Medicare's Most-Favored-Nation policy could cut initial-phase drug spending by $5.2 billion under GLOBE and $6.4 billion under GUARD. - For about three in four medicines studied, Medicare savings would equal nearly four times that drug's entire annual sales in the reference country. - Reported confidential manufacturer agreements with the Trump administration could reduce projected Medicare savings by 71% for the first 17 companies with deals.
- The Foundation for Sarcoidosis Research (FSR) announced 13 inaugural clinical sites for its national FSR Clinical Data Registry, including Brigham and Women's Hospital, Stanford, Yale, and Duke University. - The longitudinal, multi-center registry aims to improve understanding of sarcoidosis through standardized data collection across geographically and ethnically diverse patient populations. - FSR spent two years developing the protocol with input from patients, caregivers, clinicians, and pharmaceutical partners to address the disease's multi-disciplinary nature. - The registry will complement the existing FSR-SARC Patient Registry, creating a comprehensive resource to advance diagnosis, biomarker discovery, therapy assessment, and patient outcomes.
- The House Energy and Commerce Health Subcommittee convened on July 15 to examine how FDA staffing cuts and policy disruptions are undermining U.S. biomedical innovation leadership. - The layoff of 3,500 FDA employees has reduced regulatory predictability, with drug applicants receiving less guidance, fewer updates, and less predictable approval timelines. - Witnesses warned that China is investing heavily in biotechnology and clinical trials, threatening U.S. competitiveness if regulatory uncertainty persists. - The upcoming PDUFA VII reauthorization, due to Congress by January 2027, is seen as a critical opportunity for governance reform and restoring FDA credibility.
- Nurses at UMass Memorial Medical Center's University Campus voted 1,233 to 17 to authorize a 14-day strike over chronic staffing shortages and workplace safety issues. - The union says persistent staffing challenges have increased pressure on frontline workers and threatened the hospital's ability to deliver high-quality patient care. - The hospital, Central Massachusetts' only Level 1 trauma center, reported a $159.7 million operating loss for the year ending September, amid broader financial pressures. - UMass Memorial Health says it remains committed to reaching a fair agreement and has plans to maintain hospital operations should a strike occur.
- Seegnal Inc. has signed an agreement to deploy its clinical decision support platform at Nazareth Hospital EMMS, a major Israeli trauma center serving approximately 570,000 people. - The platform uses patient-specific data—including labs, renal function, and medication history—to reduce irrelevant drug safety alerts, with published research showing 94% fewer alerts compared to legacy systems. - A 2021 Drug Safety study found Seegnal's specificity was 99% versus 0.3% for a widely used hospital record system, while still identifying every case of genuine medication risk. - The World Health Organization estimates medication errors cost health systems approximately USD $42 billion annually, with roughly half of preventable patient harm related to medications.
- A randomized, double-blind, placebo-controlled trial of 600 patients found extended low-dose apixaban (2.5 mg twice daily) reduced recurrent VTE from 10% to 1.3% versus placebo (HR 0.13; 95% CI 0.04–0.36). - The trial enrolled patients with provoked VTE and persistent risk factors who had completed at least three months of anticoagulation, a group with limited prior evidence guiding extended therapy. - Major bleeding was rare and did not differ significantly between groups, though clinically relevant nonmajor bleeding was numerically more frequent with apixaban. - The single-center design at Brigham and Women's Hospital and limited power to evaluate specific risk factors represent key study limitations.
- A 2021 systematic review found forest therapy consistently associated with improvements in depression and anxiety symptoms in both healthy individuals and those with diagnosed conditions. - Harvard Medical School's Susan Abookire now guides monthly forest therapy walks for medical residents, citing research that nature activates the parasympathetic nervous system and reduces stress. - Experts emphasize that mindfulness paired with nature exposure—not merely being outdoors—drives therapeutic benefits, with as little as 5 to 10 minutes daily yielding compounding mental health gains. - Plant-derived terpenes such as d-limonene, carvacrol, and borneol are being studied for anti-inflammatory, neuroprotective, and potential anti-cancer properties.
- MIT researchers have created a hydrogel-based oral formulation that coats the esophageal lining, enabling direct drug delivery to a historically difficult-to-target tissue. - The formulation combines a polysaccharide hydrogel with bile salts (sodium chenodeoxycholate and sodium cholate) that temporarily loosen cell-cell junctions to enhance drug permeability. - In animal studies, the gel successfully delivered infliximab, an anti-TNF-alpha antibody, directly to esophageal tissue, with cell junctions returning to normal within three days. - The platform aims to reduce systemic side effects associated with immunosuppressants like infliximab by enabling site-directed delivery for conditions such as eosinophilic esophagitis and Crohn's disease.
- Nearly 4,000 registered nurses at Brigham and Women's Hospital voted overwhelmingly (2,798 to 12) to authorize a one-day strike after more than seven months of contract negotiations with Mass General Brigham. - MGB executives are offering 0% wage increases for nurses below the top step while proposing increases to health insurance costs, despite reporting a $2.4 billion net margin. - Nurses cite concerns over patient care service closures including the Weiner Center, Brigham Burn Unit, and Integrated Care Management Program as evidence of MGB prioritizing financial strategies over patient care. - The strike authorization does not guarantee a strike will occur; the next bargaining session is scheduled for June 18, and nurses would provide the legally required 10-day notice if a strike is scheduled.
- Bayer's investigational PET radiotracer I-124 evuzamitide successfully met primary endpoints for sensitivity and specificity in diagnosing cardiac amyloidosis in the Phase III REVEAL study. - The study evaluated 170 adults with suspected cardiac amyloidosis across 19 U.S. centers, demonstrating the potential for a single non-invasive diagnostic test for this underdiagnosed condition. - I-124 evuzamitide has received FDA Breakthrough Therapy Designation and Orphan Drug status, with Bayer planning regulatory discussions for approval submission. - Cardiac amyloidosis affects approximately 400,000 patients worldwide and typically requires 2-4 years from symptom onset to diagnosis due to lack of reliable diagnostic tools.
